Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)

E. A. Kogan, T. U. Manujlova, E. N. Popova, V. V. Kraeva, V. I. Osipenko, V. V. Denguine (Moscow, Russia)

Source: Annual Congress 2004 - Clinical pathobiology of interstitial lung diseases
Session: Clinical pathobiology of interstitial lung diseases
Session type: Thematic Poster Session
Number: 3315
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. A. Kogan, T. U. Manujlova, E. N. Popova, V. V. Kraeva, V. I. Osipenko, V. V. Denguine (Moscow, Russia). Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD). Eur Respir J 2004; 24: Suppl. 48, 3315

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018



ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016


A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006


Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012

Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015


Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Idiopathic pulmonary fibrosis (IPF)
Source: ERS Course 2016
Year: 2016




LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014


Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015

Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018

The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015


Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005

Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013

Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF clinical
Year: 2016

Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017

Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013